Nektar Therapeutics Operating Cash Flow
Nektar Therapeutics (NKTR) reported Operating Cash Flow of -$120.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Nektar Therapeutics net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$75.77M.
- Nektar Therapeutics net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$44.30M.
- Nektar Therapeutics net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$64.96M.
- Nektar Therapeutics net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$48.76M.
- Nektar Therapeutics net cash provided by (used in) operating activities for fiscal 2025 was -$208.51M.
- Nektar Therapeutics net cash provided by (used in) operating activities for fiscal 2024 was -$175.71M.
- Nektar Therapeutics net cash provided by (used in) operating activities for fiscal 2023 was -$192.61M.
- Nektar Therapeutics net cash provided by (used in) operating activities for fiscal 2022 was -$304.01M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$75.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$120.07M 10-Q · filed 2026-08-14 | -$185.03M derived: sum of 3 quarters · filed 2026-08-14 | -$233.79M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$44.30M 10-Q · filed 2026-05-08 | -$109.26M derived: sum of 2 quarters · filed 2026-05-08 | -$158.02M derived: sum of 3 quarters · filed 2026-05-08 | -$203.76M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$64.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$113.72M derived: sum of 2 quarters · filed 2026-03-13 | -$159.46M derived: sum of 3 quarters · filed 2026-08-14 | -$208.51M 10-K · filed 2026-03-13 |
| 2025-09-30 | -$48.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$94.50M derived: sum of 2 quarters · filed 2026-08-14 | -$143.55M 10-Q · filed 2025-11-07 | -$189.74M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$45.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$94.79M 10-Q · filed 2026-08-14 | -$140.98M derived: sum of 3 quarters · filed 2026-08-14 | -$184.91M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$49.05M 10-Q · filed 2026-05-08 | -$95.24M derived: sum of 2 quarters · filed 2026-05-08 | -$139.17M derived: sum of 3 quarters · filed 2026-05-08 | -$176.87M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$46.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$90.12M derived: sum of 2 quarters · filed 2026-03-13 | -$127.82M derived: sum of 3 quarters · filed 2026-03-13 | -$175.71M 10-K · filed 2026-03-13 |
| 2024-09-30 | -$43.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$81.63M derived: sum of 2 quarters · filed 2025-11-07 | -$129.52M 10-Q · filed 2025-11-07 | -$176.57M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$37.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$85.59M 10-Q · filed 2025-08-08 | -$132.64M derived: sum of 3 quarters · filed 2025-08-08 | -$174.76M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | -$47.89M 10-Q · filed 2025-05-09 | -$94.94M derived: sum of 2 quarters · filed 2025-05-09 | -$137.06M derived: sum of 3 quarters · filed 2025-05-09 | -$188.58M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$47.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | -$89.17M derived: sum of 2 quarters · filed 2025-03-14 | -$140.69M derived: sum of 3 quarters · filed 2025-03-14 | -$192.61M 10-K · filed 2025-03-14 |
| 2023-09-30 | -$42.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$93.64M derived: sum of 2 quarters · filed 2024-11-08 | -$145.56M 10-Q · filed 2024-11-08 | -$203.26M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | -$51.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$103.44M 10-Q · filed 2024-08-09 | -$161.14M derived: sum of 3 quarters · filed 2024-08-09 | -$244.03M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | -$51.91M 10-Q · filed 2024-05-10 | -$109.62M derived: sum of 2 quarters · filed 2024-05-10 | -$192.50M derived: sum of 3 quarters · filed 2024-05-10 | -$267.50M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$57.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$140.59M derived: sum of 2 quarters · filed 2024-03-05 | -$215.58M derived: sum of 3 quarters · filed 2024-03-05 | -$304.01M 10-K · filed 2024-03-05 |
| 2022-09-30 | -$82.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$157.88M derived: sum of 2 quarters · filed 2023-11-08 | -$246.30M 10-Q · filed 2023-11-08 | -$397.84M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | -$74.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$163.42M 10-Q · filed 2023-08-09 | -$314.95M derived: sum of 3 quarters · filed 2024-03-05 | -$416.09M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | -$88.42M 10-Q · filed 2023-05-10 | -$239.96M derived: sum of 2 quarters · filed 2024-03-05 | -$341.10M derived: sum of 3 quarters · filed 2024-03-05 | -$424.00M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | -$151.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$252.67M derived: sum of 2 quarters · filed 2024-03-05 | -$335.57M derived: sum of 3 quarters · filed 2024-03-05 | -$412.66M 10-K · filed 2024-03-05 |
| 2021-09-30 | -$101.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$184.04M derived: sum of 2 quarters · filed 2022-11-04 | -$261.12M 10-Q · filed 2022-11-04 | -$359.76M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$82.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$159.99M 10-Q · filed 2022-08-05 | -$258.62M derived: sum of 3 quarters · filed 2023-02-28 | -$311.30M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$77.08M 10-Q · filed 2022-05-06 | -$175.72M derived: sum of 2 quarters · filed 2023-02-28 | -$228.39M derived: sum of 3 quarters · filed 2023-02-28 | -$312.30M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$98.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$151.31M derived: sum of 2 quarters · filed 2023-02-28 | -$235.21M derived: sum of 3 quarters · filed 2023-02-28 | -$313.29M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$52.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$136.58M derived: sum of 2 quarters · filed 2021-11-05 | -$214.65M 10-Q · filed 2021-11-05 | -$339.88M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$83.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | -$161.98M 10-Q · filed 2021-08-06 | -$287.20M derived: sum of 3 quarters · filed 2022-03-01 | -$355.84M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$78.08M 10-Q · filed 2021-05-07 | -$203.30M derived: sum of 2 quarters · filed 2022-03-01 | -$271.94M derived: sum of 3 quarters · filed 2022-03-01 | -$325.86M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$125.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$193.86M derived: sum of 2 quarters · filed 2022-03-01 | -$247.79M derived: sum of 3 quarters · filed 2022-03-01 | -$328.68M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$68.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$122.56M derived: sum of 2 quarters · filed 2020-11-06 | -$203.46M 10-Q · filed 2020-11-06 | -$321.01M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$53.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$134.82M 10-Q · filed 2020-08-07 | -$252.37M derived: sum of 3 quarters · filed 2021-02-26 | -$323.78M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$80.89M 10-Q · filed 2020-05-08 | -$198.44M derived: sum of 2 quarters · filed 2021-02-26 | -$269.86M derived: sum of 3 quarters · filed 2021-02-26 | $689.78M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$117.55M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$188.96M derived: sum of 2 quarters · filed 2021-02-26 | $770.68M derived: sum of 3 quarters · filed 2021-02-26 | $718.21M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$71.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $888.23M derived: sum of 2 quarters · filed 2019-11-07 | $835.76M 10-Q · filed 2019-11-07 | $755.36M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $959.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $907.18M 10-Q · filed 2019-08-09 | $826.77M derived: sum of 3 quarters · filed 2020-02-28 | $919.85M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-03-31 | -$52.47M 10-Q · filed 2019-05-09 | -$132.87M derived: sum of 2 quarters · filed 2020-02-28 | -$39.79M derived: sum of 3 quarters · filed 2020-02-28 | |
| 2017-12-31 | -$80.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $12.68M derived: sum of 2 quarters · filed 2020-02-28 | -$80.41M 10-K · filed 2020-02-28 | |
| 2017-09-30 | $93.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$13.00K 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | -$93.09M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | -$117.02M 10-K · filed 2019-03-01 | |||
| 2013-12-31 | $53.63M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | $33.92M derived: sum of 2 quarters · filed 2014-02-27 | -$416.00K derived: sum of 3 quarters · filed 2014-02-27 | -$38.53M 10-K · filed 2014-02-27 |
| 2013-09-30 | -$19.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$54.05M derived: sum of 2 quarters · filed 2013-11-07 | -$92.16M 10-Q · filed 2013-11-07 | -$139.53M derived: sum of 4 quarters · filed 2014-02-27 |
| 2013-06-30 | -$34.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$72.45M 10-Q · filed 2013-08-09 | -$119.82M derived: sum of 3 quarters · filed 2014-02-27 | -$147.00M derived: sum of 4 quarters · filed 2014-02-27 |
| 2013-03-31 | -$38.11M 10-Q · filed 2013-05-09 | -$85.49M derived: sum of 2 quarters · filed 2014-02-27 | -$112.66M derived: sum of 3 quarters · filed 2014-02-27 | -$133.25M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-12-31 | -$47.38M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | -$74.55M derived: sum of 2 quarters · filed 2014-02-27 | -$95.14M derived: sum of 3 quarters · filed 2014-02-27 | -$129.76M 10-K · filed 2014-02-27 |
| 2012-09-30 | -$27.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$47.76M derived: sum of 2 quarters · filed 2013-11-07 | -$82.38M 10-Q · filed 2013-11-07 | -$124.59M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | -$20.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$55.21M 10-Q · filed 2013-08-09 | -$97.42M derived: sum of 3 quarters · filed 2014-02-27 | -$119.29M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | -$34.62M 10-Q · filed 2013-05-09 | -$76.83M derived: sum of 2 quarters · filed 2014-02-27 | -$98.70M derived: sum of 3 quarters · filed 2014-02-27 | -$133.49M derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | -$42.21M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | -$64.08M derived: sum of 2 quarters · filed 2014-02-27 | -$98.87M derived: sum of 3 quarters · filed 2014-02-27 | -$113.74M 10-K · filed 2014-02-27 |
| 2011-09-30 | -$21.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | -$56.66M derived: sum of 2 quarters · filed 2012-11-09 | -$71.53M 10-Q · filed 2012-11-09 | -$51.12M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | -$34.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | -$49.66M 10-Q · filed 2012-08-09 | -$29.25M derived: sum of 3 quarters · filed 2013-03-01 | -$51.41M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | -$14.87M 10-Q · filed 2012-05-04 | $5.54M derived: sum of 2 quarters · filed 2013-03-01 | -$16.63M derived: sum of 3 quarters · filed 2013-03-01 | -$36.58M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | $20.41M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | -$1.75M derived: sum of 2 quarters · filed 2013-03-01 | -$21.71M derived: sum of 3 quarters · filed 2013-03-01 | -$55.87M 10-K · filed 2013-03-01 |
| 2010-09-30 | -$22.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | -$42.12M derived: sum of 2 quarters · filed 2011-11-04 | -$76.28M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | -$19.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | -$54.12M 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | -$34.16M 10-Q · filed 2011-04-29 | |||
| 2009-12-31 | $39.74M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |